Live Breaking News & Updates on Malignant Hematology

Stay updated with breaking news from Malignant hematology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need

"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology. ....

United States , Frederickl Locke , Bristol Myers Squibb Breyanzi , Javier Pinilla Ibarz , David Chang , Department Of Malignant Hematology , Bristol Myers Squibb , Moffitt Cancer Center Lymphoma Section , Cell Therapy Initiative , Moffitt Cancer Center , Lymphoma Section , Malignant Hematology , Allogene Therapeutics , Current Oncology , Cell Exhaustion , Cell Therapy , Address Unmet , Bristol Myers Squib , Moffitt Cancer , Immune Cell Therapy Initiative , Allogene President , Updated April ,

Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy. ....

Ariel Grajales Cruz , Department Of Malignant Hematology , Moffitt Cancer Center , University Of South Florida , Malignant Hematology , Multiple Myeloma Section , South Florida , Patients With Myeloma Who Had Received Bcma Directed Therapy ,

Dr Baz on AE Management Discussions in Multiple Myeloma

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments. ....

Rachid Baz , Moffitt Cancer Center , Department Of Malignant Hematology , Pentecost Family Myeloma Research Center , Malignant Hematology , Multiple Myeloma Treatments ,

New Treatments for Newly Diagnosed MM Offer a Lot of Benefit, but Key Knowledge Gaps Remain

While there is, rightfully, a lot of optimism around the latest treatments for newly diagnosed multiple myeloma, not everyone is gaining the same benefit, said Kenneth Shain, MD, PhD, of H. Lee Moffitt Cancer Center. ....

United States , Kenneth Shain , Pentecost Myeloma Research Center , H Lee Moffitt Cancer Center Kenneth Shain , H Lee Moffitt Cancer Center , Moffitt Cancer Center , Malignant Hematology , Chemical Biology , Molecular Medicine , Moffitt Cancer , American Journal , Managed Care ,

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma. ....

Hayder Saeed , International Prognostic Index , Moffitt Cancer Center , Malignant Hematology , Bridging The Gaps , Hematologic Malignancies ,